Dendritic cells: The driver of psoriasis

J Dermatol. 2020 Feb;47(2):104-113. doi: 10.1111/1346-8138.15184. Epub 2019 Dec 13.

Abstract

Psoriasis is a chronic skin inflammatory disorder, the immune mechanism of which has been profoundly elucidated in the past few years. The dominance of the interleukin (IL)-23/IL-17 axis is a significant breakthrough in the understanding of the pathogenesis of psoriasis, and treatment targeting IL-23 and IL-17 has successfully benefited patients with the disease. The skin contains a complex network of dendritic cells (DC) mainly composed of epidermal Langerhans cells, bone marrow-derived dermal conventional DC, plasmacytoid DC and inflammatory DC. As the prominent cellular source of α-interferon, tumor necrosis factor-α, IL-12 and IL-23, DC play a pivotal role in psoriasis. Thus, targeting pathogenic DC subsets is a valid strategy for alleviating and preventing psoriasis and other DC-derived diseases. In this review, we survey the known role of DC in this disease.

Keywords: Langerhans cells; dendritic cells; interleukin-23; psoriasis; α-interferon.

Publication types

  • Review

MeSH terms

  • Animals
  • Dendritic Cells / drug effects
  • Dendritic Cells / immunology*
  • Dendritic Cells / metabolism
  • Dermatologic Agents / pharmacology
  • Dermatologic Agents / therapeutic use
  • Disease Models, Animal
  • Humans
  • Interferon-alpha / metabolism
  • Interleukin-17 / antagonists & inhibitors
  • Interleukin-17 / metabolism
  • Interleukin-23 / antagonists & inhibitors
  • Interleukin-23 / metabolism
  • Psoriasis / drug therapy
  • Psoriasis / immunology*
  • Psoriasis / pathology
  • Signal Transduction / drug effects
  • Signal Transduction / immunology
  • Skin / cytology
  • Skin / immunology
  • Skin / pathology
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Dermatologic Agents
  • Interferon-alpha
  • Interleukin-17
  • Interleukin-23
  • Tumor Necrosis Factor-alpha